Key features and details
- Mouse monoclonal [4D6] to MyD88
- Suitable for: WB, Flow Cyt, ICC/IF
- Knockout validated
- Reacts with: Human
- Isotype: IgG1
Product nameAnti-MyD88 antibody [4D6]
See all MyD88 primary antibodies
DescriptionMouse monoclonal [4D6] to MyD88
SpecificityEspected to recognise Isoforms 1, 3, 4, 5, CRAa and CRAb.
Tested applicationsSuitable for: WB, Flow Cyt, ICC/IFmore details
Species reactivityReacts with: Human
Synthetic peptide, corresponding to amino acids 50-100 of Human MyD88 (NP_002459).
- human ovary, human prostate and Jurkat cell lysates and CF-7 cells.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: PBS, 0.05% BSA
Concentration information loading...
PurityProtein G purified
Light chain typekappa
Our Abpromise guarantee covers the use of ab107585 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 5 - 7 µg/ml. Predicted molecular weight: 33 kDa.|
|Flow Cyt||Use 0.5µg for 106 cells.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
|ICC/IF||Use a concentration of 5 µg/ml.|
FunctionAdapter protein involved in the Toll-like receptor and IL-1 receptor signaling pathway in the innate immune response. Acts via IRAK1, IRAK2, IRF7 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Increases IL-8 transcription. Involved in IL-18-mediated signaling pathway.
Involvement in diseaseDefects in MYD88 are the cause of MYD88 deficiency (MYD88D) [MIM:612260]; also known as recurrent pyogenic bacterial infections due to MYD88 deficiency. Patients suffer from autosomal recessive, life-threatening, often recurrent pyogenic bacterial infections, including invasive pneumococcal disease, and die between 1 and 11 months of age. Surviving patients are otherwise healthy, with normal resistance to other microbes, and their clinical status improved with age.
Sequence similaritiesContains 1 death domain.
Contains 1 TIR domain.
DomainThe intermediate domain (ID) is required for the phosphorylation and activation of IRAK.
- Information by UniProt
- Mutant myeloid differentiation primary response 88 antibody
- MYD 88 antibody
- Myd88 antibody
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: MyD88 knockout HAP1 cell lysate (20 µg)
Lane 3: Jurkat cell lysate (20 µg)
Lane 4: MOLT4 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab107585 observed at 37 kDa. Red - loading control, ab176560, observed at 52 kDa.
ab107585 was shown to recognize MyD88 when MyD88 knockout samples were used, along with additional cross-reactive bands. Wild-type and MyD88 knockout samples were subjected to SDS-PAGE. ab107585 and ab176560 (loading control to alpha tubulin) were diluted 5 µg/mL and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772 and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
Intracellular flow cytometric analysis of MyD88 antibody (ab107585) in Jurkat cells (0.5 ug). Shaded histogram represents cells without antibody; green represents isotype control; red represents anti-MyD88 antibody. Secondary antibody- anti-mouse IgG PE conjugated.
Immunocytochemical analysis of MyD88 antibody (ab107585) in MCF-7 cells using an isotype control (top) and Myd88 Antibody (5 µg/ml; bottom).
All lanes : Anti-MyD88 antibody [4D6] (ab107585) at 5 µg/ml
Lane 1 : Human ovary cell lysate
Lane 2 : Human prostate cell lysate
Lane 3 : Jurkat cell lysate
Lane 4 : Jurkat cell lysate with Immunizing peptide
All lanes : Goat anti-mouse Ig HRP
Predicted band size: 33 kDa
ab107585 has been referenced in 1 publication.
- Sun Y et al. Exercise intervention alleviates nerve injury by the suppression of inflammatory mediator expression via the TLR4/NF-?B signaling pathway. Exp Ther Med 16:2922-2930 (2018). PubMed: 30233666